Direct answer
Selected St John’s wort extracts show depression benefit but have documented serious interactions. Saffron and L-theanine evidence remains limited; the L-theanine GAD trial was negative. Vitamin D did not prevent depression in the studied older population, and other products have mixed evidence or safety limits.
- St John’s wort has a depression benefit signal in a Cochrane review, alongside documented serious interactions. This article does not establish a universal supplement ranking or that it is as safe as an antidepressant. Source 1. Source 2.
- L-theanine and saffron have preliminary signals for stress responses and mild depressive symptoms respectively. Larger trials, clearer funding and better long-term safety evidence are needed; lower risk than other supplements is not established. Source 1. Source 2.
- Magnesium and vitamin D are adequacy tools, not mood cures: the VITAL-DEP trial found no depression-prevention benefit over 5.3 years in adults aged 50+ without clinically relevant baseline symptoms, and magnesium’s anxiety evidence is rated poor quality.
- Kava carries rare but serious liver-injury risk (including liver-transplant cases) and NCCIH says it doesn’t clearly help generalized anxiety disorder — a poor risk/benefit trade.
- Homeopathic anxiety remedies, “happy pill” blends, casual 5-HTP stacking, and broad CBD mental-health claims are the biggest hype-to-evidence gaps in this category.
Ingredient evidence review · Funding and conflict traced
The most defensible supplements for stress, anxiety, or mild depressive symptoms are adjuncts, not cures: selected St John’s wort extracts have depression benefit signals and documented serious interactions; saffron, L-theanine, selected ashwagandha preparations and omega-3 have limited or mixed evidence; magnesium and vitamin D mainly make sense when intake or status is low. Popular “happy pills,” homeopathic anxiety remedies, CBD mental-health overclaims, 5-HTP stacks, kava anxiety products, and broad adaptogen blends either have weak evidence, safety problems, or marketing that outruns clinical proof (NCCIH St John’s wort, Cochrane omega-3 depression review, NCCIH kava).
Supplements should not be used as the primary plan for severe depression, suicidal thoughts, panic that prevents normal life, psychosis, mania, substance dependence, postpartum depression, or inability to sleep, eat, work, study, or care for dependents. WHO states that effective treatments exist for depression and anxiety disorders, and these conditions can cause severe impairment and suicide risk (WHO depression fact sheet, WHO anxiety disorders fact sheet).
Table of contents
- Evidence summary
- Bottom line: what is worth considering
- The evidence tiers
- Proven or promising ingredients
- Popular supplements with weak, mixed, or no useful evidence
- All forms and types
- What works and what does not
- Risks and all side effects
- All interactions
- Frequently asked questions
- Sources
Evidence summary
| Ingredient / claim | Evidence | Funding / conflict tracing | Verdict |
|---|---|---|---|
| St John’s wort for mild-to-moderate depression | Cochrane reviewed 29 trials with 5,489 patients and found St John’s wort extracts superior to placebo, similarly effective to standard antidepressants, and with fewer side effects than standard antidepressants in trials. | Cochrane public summary does not show funding for every included trial; herbal-product trial fields have manufacturer and regional bias risks, so the efficacy conclusion is paired with strict interaction warnings. | Works, but high-risk Cochrane |
| St John’s wort safety | NCCIH warns it can interact with antidepressants and other serotonin-affecting drugs in ways that may be serious, and interaction reviews describe CYP and P-glycoprotein mechanisms. | NCCIH supplies public clinical guidance. Mannel’s public author manuscript discloses former employment and paid consulting for St John’s wort manufacturer Lichtwer Pharma, which also supplied free literature-database access. The final publisher version was not recovered. | Documented serious interactions: NCCIH / PubMed interaction review Source 1 Source 2 |
| Omega-3 supplements for depression | Cochrane found insufficient high-certainty evidence for omega-3 in major depressive disorder; NCCIH says any effect may be too small to be meaningful. | Cochrane’s public summary does not expose complete review and included-trial finances; NCCIH is a government information source. Complete trial funding and product-supply arrangements remain unverified. | Mixed adjunct Cochrane / NCCIH omega-3 |
| Ashwagandha for stress or sleep | NCCIH says some preparations may be effective for insomnia and stress, but long-term safety conclusions cannot be made and rare liver injury cases have been linked to supplements. | NCCIH provides government guidance; the complete finances of the efficacy studies it summarizes were not traced here. The case series provides clinical safety signals and cannot estimate injury frequency. | Promising but safety-limited NCCIH / liver injury case series |
| L-theanine for stress/anxiety | A systematic review of human RCTs concluded 200–400 mg/day may reduce stress and anxiety in people exposed to stressful conditions, while calling for larger and longer studies. | The accepted review manuscript reports Australian Government research-training scholarships for two authors and a Dementia Australia Research Foundation scholarship for one. No conflict declaration was located in that version; included-trial funding and product-supply arrangements were not all traced. | Preliminary short-term stress evidence L-theanine review |
| Saffron for mild-to-moderate depression | Small trials suggest benefit versus placebo; pooled comparisons with antidepressants did not show a significant difference. This does not establish noninferiority or equivalence. | Hausenblas 2013 disclosed Reserveage Organics funding and two author adviser/consultant ties to its saffron product. Tóth 2019 declared no conflicts; its official repository record names Hungarian public research grants and an Academy scholarship. Full methods and complete underlying-trial finances remain unverified. | Preliminary, commercially linked context Source 1 Source 2 |
| Magnesium for anxiety/stress | A systematic review found suggestive benefit for subjective anxiety in vulnerable samples but concluded evidence quality was poor and better RCTs are needed. | Sanofi financed the initial systematic search and supplied three unpublished studies; one author served on its Consumer Healthcare Advisory Board. The review reports poor-quality, suggestive evidence and is commercially linked. | Suggestive only magnesium review |
| Vitamin D for depression prevention | VITAL-DEP found no significant reduction in depression incidence, recurrence or mood-score change over 5.3 years among adults aged 50+ without clinically relevant baseline symptoms. Most had adequate vitamin D status. | NIH supported VITAL-DEP; Pharmavite and Pronova/BASF donated agents, placebos and packaging. Disclosures include Pharmavite consulting/fees and an author’s spouse on its advisory board. Sponsors reportedly had no study or manuscript role; a null result does not establish independence. Trial disclosures. | Doesn’t prevent depression broadly VITAL-DEP |
| Homeopathic anxiety remedies | A systematic review found evidence for homeopathy in anxiety and anxiety disorders was limited, contradictory, underpowered, or insufficient for firm conclusions; another psychiatry review found efficacy not shown for anxiety or stress. | Davidson 2011 reports partial U.S. Army funding and author pharmaceutical consulting/royalties. Pilkington2006 complete funding disclosures were not accessible. Field-allegiance is a separate potential incentive, not proof of funding. | No useful evidence homeopathy anxiety review / psychiatry homeopathy review Source 1 Source 2 |
| Kava for anxiety | NCCIH says kava supplements may help anxiety after several weeks but do not appear helpful for generalized anxiety disorder symptoms; rare severe or fatal liver injury cases are a major safety issue. | NCCIH and NIH ODS are government sources; kava clinical trials and product variability create uncertainty. | Mixed evidence, serious risk NCCIH kava / NIH ODS kava |
| CBD for anxiety/depression overclaims | Han 2024 pooled eight heterogeneous studies, including three open-label studies and uncontrolled data; the low-risk subgroup did not show a significant effect. This is not proof of a broad anxiety or depression treatment. | Han 2024 declares no known competing interests but gives no located funding statement and includes a hemp-industry-technology laboratory affiliation. Underlying trial finances remain unverified. | Overclaimed CBD RCT review / CBD meta-analysis Source |
| 5-HTP for depression | Cochrane review found few reliable studies despite possible benefit signals and concluded clinical usefulness is limited because effective and safer alternatives exist. | Old, small trials and incomplete safety evidence downgrade confidence; serotonin-syndrome concern is mechanistically plausible and reviewed in pharmacology literature. | Overhyped and interaction-prone Cochrane 5-HTP review / 5-HTP safety review |
Bottom line: what is worth considering
Evidence of benefit does not establish comparative safety. St John’s wort has a real signal for mild-to-moderate depression in trials, but it is often the wrong self-care choice because it can interact with antidepressants, anticoagulants, oral contraceptives, transplant medicines, HIV medicines, seizure medicines, digoxin, cancer medicines, and many other drugs through serotonin effects, CYP induction, and P-glycoprotein induction (NCCIH St John’s wort, St John’s wort interaction review).
Possible adjunct discussions include L-theanine for stress responses and saffron for mild depressive symptoms, but benefits and comparative safety remain uncertain. Omega-3 depression evidence is mixed; magnesium and vitamin D should reflect nutritional status. These findings do not identify a generally safest mood supplement. Source 1. Source 2. Source 3.
Supplement evidence tiers for stress anxiety and depression
Read the practical summary
- Tier 1: St John’s wort works for some mild-to-moderate depression trials, but the interaction burden is high.
- Tier 2: Saffron, L-theanine, and selected ashwagandha preparations are promising adjuncts with important evidence and safety limits.
- Tier 3: Magnesium and vitamin D decisions should reflect nutritional status. Omega-3 depression evidence is uncertain and does not establish a preferred EPA formula.
- Tier 4: Homeopathy, “happy pill” blends, CBD cure claims, casual 5-HTP stacks, and do-it-yourself kava are not supported as reliable mental-health treatments.
The evidence tiers
Tier 1: studied depression benefit with serious interaction risks
St John’s wort is the clearest example of why “natural” does not mean “safe.” Cochrane found benefit in depression trials, while NCCIH warns about serious interactions with antidepressants and other serotonin-affecting drugs and about compromised effects of other medicines (Cochrane St John’s wort, NCCIH St John’s wort). The editorial verdict is narrow: it may be considered only for mild-to-moderate depression when a qualified clinician or pharmacist has ruled out medication, pregnancy, bipolar-spectrum, transplant, HIV, cancer-treatment, seizure, anticoagulant, and contraceptive risks.
Tier 2: promising adjuncts with limits
Saffron has small-study placebo benefit signals, but null antidepressant comparisons do not establish equivalence or noninferiority. Tóth 2019 declared no conflicts; its official repository record names Hungarian public research grants and an Academy scholarship. Full methods and complete underlying-trial finances remain unverified. L-theanine has a limited short-term stress signal and selected ashwagandha preparations may help stress or insomnia; longer trials and medication checks remain necessary. Source 1. Source 2. Source 3.
Tier 3: adequacy and deficiency tools
Magnesium may help subjective anxiety in vulnerable samples, but the systematic review found the evidence poor and in need of better RCTs (magnesium review). Vitamin D supports bone and mineral physiology, but VITAL-DEP did not support vitamin D3 for broad depression prevention in adults aged 50+ without clinically relevant depressive symptoms at baseline (VITAL-DEP, NIH ODS vitamin D). Omega-3 is biologically plausible and useful for some non-mood indications, but Cochrane says high-certainty evidence is insufficient for major depressive disorder and NCCIH says any depression effect may be too small to be meaningful (Cochrane omega-3 depression review, NCCIH omega-3).
Tier 4: popular claims to downgrade or reject
Homeopathic anxiety remedies do not have reliable evidence for anxiety disorders: one systematic review found limited and contradictory evidence, and a psychiatry review found efficacy not shown for anxiety or stress (homeopathy anxiety review, homeopathy psychiatry review). Kava has a mixed anxiety signal but carries rare severe liver-injury risk, and NCCIH says kava does not appear helpful for generalized anxiety disorder symptoms (NCCIH kava). CBD has early anxiety signals in small heterogeneous trials, but reviews call for better RCTs and do not justify broad anxiety/depression cure marketing (CBD RCT review, CBD meta-analysis). 5-HTP is overhyped because the Cochrane review found few reliable studies and stated clinical usefulness is limited, while pharmacology reviews discuss serotonin syndrome and other safety issues (Cochrane 5-HTP review, 5-HTP safety review).
Proven or promising ingredients
Omega-3 EPA: mixed depression evidence, plausible adjunct
EPA and DHA are long-chain omega-3 fatty acids found in fish oil, krill oil, cod liver oil, algal oil, and some prescription products, while ALA from flax/chia/walnuts converts inefficiently to EPA/DHA, with NIH ODS reporting conversion rates typically below 15% (NIH ODS omega-3). For depression, the best conservative conclusion is “possible adjunct, not primary treatment,” because Cochrane found insufficient high-certainty evidence for omega-3 in major depression and NCCIH says any effect may be too small to be meaningful (Cochrane omega-3 depression review, NCCIH omega-3).
St John’s wort: effective enough to be dangerous
St John’s wort should be written about like an active drug, not a wellness tea. Cochrane found trial benefits for depression, but NCCIH warns about serious serotonin-related interactions and drug-effect compromise, and PubMed-indexed reviews describe pharmacokinetic interactions involving CYP enzymes and P-glycoprotein (Cochrane St John’s wort, NCCIH St John’s wort, St John’s wort interaction review).
Ashwagandha: stress signal plus liver and pregnancy caution
Ashwagandha is most defensible as a short-term stress or insomnia adjunct using studied preparations, not as a broad anxiety/depression treatment. NCCIH says some preparations may be effective for insomnia and stress, but long-term safety conclusions cannot be reached and rare liver injury cases have been linked to ashwagandha supplements (NCCIH ashwagandha).
L-theanine: short-term stress support
L-theanine has preliminary short-term stress-response evidence. The review included nine studies with 270 participants and suggested 200–400 mg/day may help under stressful conditions. Its 46-person generalized-anxiety-disorder trial, using 450–900 mg/day, found no anxiety or mood advantage over placebo. Larger and longer trials are needed before treating it as an anxiety therapy (L-theanine review, accepted author manuscript).
Saffron: promising for mild-to-moderate depression
Small saffron trials suggest short-term depressive-symptom benefit over placebo. They do not prove equivalence to prescription antidepressants. The five-trial 2013 review used small single-center Iran studies and disclosed Reserveage Organics funding plus adviser/consultant ties; its favorable results are commercial context, not independent confirmation. The 2019 review’s repository record names Hungarian public grants and an Academy scholarship; full methods, underlying-trial finances and longer-term replication still require verification. Source 1. Source 2.
Promising supplement roles
Read the practical summary
| Ingredient | Most defensible role | Non-negotiable caveat |
|---|---|---|
| St John’s wort | Mild-to-moderate depression. | High interaction burden; do not combine with many medicines without professional review. |
| L-theanine | Stress response and situational anxiety support. | Evidence is short-term and not a treatment for severe anxiety. |
| Saffron | Mild-to-moderate depressive symptoms. | More independent long-term replication needed. |
| Ashwagandha | Stress and sleep support. | Rare liver injury and pregnancy/thyroid/immune cautions. |
Popular supplements with weak, mixed, or no useful evidence
Homeopathic anxiety remedies
Homeopathic anxiety remedies should not be presented as evidence-based anxiety treatment. A systematic review concluded evidence for anxiety and anxiety disorders was limited, contradictory, underpowered, or insufficient for firm conclusions, and a psychiatry-focused review found efficacy not shown for anxiety or stress (homeopathy anxiety review, homeopathy psychiatry review).
“Happy pill” blends
“Happy pill,” “mood cure,” and “anxiety cure” blends commonly combine serotonergic ingredients, sedating herbs, adaptogens, amino acids, and vitamins without testing the exact blend in high-quality clinical trials. The evidence problem is not that every component is useless; the problem is that a proprietary combination can inherit every interaction risk while having none of the single-ingredient evidence.
Kava
Kava is not a clean win. NCCIH states kava supplements may help anxiety but may need weeks to work, do not appear helpful for generalized anxiety disorder symptoms, and have been linked to rare cases of severe or fatal liver injury (NCCIH kava). NIH ODS notes reports of hepatitis, cirrhosis, liver failure, and a liver-transplant case in kava-associated safety reports (NIH ODS kava).
Adaptogen hype
Ashwagandha has some evidence, but broad adaptogen claims often extrapolate from stress markers, animal studies, proprietary trials, or traditional-use narratives to claims about depression and anxiety disorders. If a blend contains ashwagandha, rhodiola, ginseng, schisandra, holy basil, mushrooms, or sedating herbs, treat it as a multi-drug exposure and ask for exact human RCT evidence on that exact formula.
CBD mental-health overclaims
CBD has preliminary anxiety signals, but the cited Han 2024 meta-analysis mixes randomized and open-label/uncontrolled studies, includes different populations and has high heterogeneity. Its low-risk subgroup was not significant. These findings do not establish broad anxiety or depression treatment. Medication interactions and product-specific safety require separate clinical review. Source 1. Source 2.
5-HTP
5-HTP is a serotonin precursor, which makes it pharmacologically active rather than harmless. A Cochrane review found possible benefit signals but few studies of sufficient quality and limited clinical usefulness, while a pharmacology review discusses serotonin syndrome and eosinophilia-myalgia syndrome safety issues (Cochrane 5-HTP review, 5-HTP safety review).
All forms and types
| Ingredient | Commercial forms / types | What matters clinically | Evidence verdict |
|---|---|---|---|
| Omega-3 | Fish oil, krill oil, cod liver oil, algal EPA/DHA, ethyl ester, triglyceride/re-esterified triglyceride, phospholipid forms, ALA oils such as flax/chia. | EPA/DHA are the relevant long-chain forms; ALA conversion to EPA/DHA is limited; cod liver oil also contains vitamins A and D. | Mixed for depression NIH ODS |
| St John’s wort | Standardized extracts, capsules/tablets, teas, tinctures, combination mood formulas. | Trial results are extract-specific; teas/tinctures may not match studied hypericin/hyperforin profiles; hyperforin-rich products may have stronger interaction potential. | Works but high-risk Cochrane |
| Ashwagandha | Root powder, root extract, root+leaf extract, standardized withanolide extracts, gummies, sleep/stress blends. | Evidence is preparation-specific; root and root+leaf products are not interchangeable; long-term safety is uncertain. | Promising for stress/sleep NCCIH |
| L-theanine | Pure L-theanine capsules/tablets, green tea-derived products, caffeine+theanine formulas, drinks and powders. | Pure L-theanine evidence should not be used to justify high-caffeine energy products; caffeine can worsen anxiety in some people. | Promising short-term PubMed |
| Saffron | Whole stigma, stigma extract, petal extract, standardized crocin/safranal extracts, combination mood formulas. | Depression trials usually use standardized extracts or defined doses; culinary saffron use is not equivalent to trial dosing. | Promising PubMed |
| Magnesium | Glycinate, citrate, oxide, chloride, malate, taurate, threonate, topical magnesium, multi-mineral blends. | Elemental magnesium dose and GI tolerance matter; magnesium binds some medicines; kidney function matters more than form hype. | Suggestive for anxiety PubMed / NIH ODS |
| Vitamin D | D3/cholecalciferol, D2/ergocalciferol, calcifediol, drops, tablets, softgels, sprays, fortified foods, high-dose regimens. | Correct deficiency under appropriate testing/clinical context; excess can cause hypercalcemia; not proven for broad depression prevention. | Deficiency tool VITAL-DEP |
| Kava | Water extracts, ethanolic/acetonic extracts, capsules, tinctures, teas, instant powders, standardized kavalactone products. | Product part, cultivar, extraction solvent, alcohol use, and contamination/adulteration may affect liver risk. | Mixed/risky NCCIH |
| CBD | Isolate, broad-spectrum, full-spectrum, oils, gummies, capsules, drinks, vapes, topical products. | Products vary widely; THC contamination, drug interactions, sedation, and liver-enzyme effects matter; mental-health claims are overbroad. | Overclaimed PubMed |
| 5-HTP | Capsules/tablets and sleep/mood blends; sometimes combined by users with other mood supplements or prescribed serotonergic medicines. | Serotonin precursor with weak efficacy evidence; serotonin-syndrome concern with serotonergic combinations is theoretical in the 2005 safety review, so medication advice is appropriate. | Overhyped Cochrane/PMC; 2005 safety review |
What works and what does not
| Claim | Verdict | Evidence | Key caveat |
|---|---|---|---|
| St John’s wort helps mild-to-moderate depression. | WORKS | Cochrane trial review. | Serious interactions make it unsuitable for many people. |
| Saffron helps mild-to-moderate depressive symptoms. | PROMISING | Meta-analyses of small RCTs. | Need larger independent long-term trials. |
| L-theanine helps stress/anxiety response. | PROMISING | Systematic review of human RCTs. | Not a treatment for anxiety disorders by itself. |
| Ashwagandha helps stress/sleep. | PROMISING | NCCIH summary of selected preparations. | Liver, pregnancy, thyroid, immune, and sedative cautions. |
| Omega-3 treats major depression. | MIXED | Cochrane says high-certainty evidence is insufficient. | Nutritional adequacy is a separate aim; the cited Cochrane review does not establish a preferred EPA formula or a reliable depression-treatment benefit. |
| Magnesium calms anxiety for everyone. | INSUFFICIENT | Suggestive but poor-quality evidence. | Best framed as adequacy/deficiency support. |
| Vitamin D prevents depression in adults generally. | DOESN’T | VITAL-DEP was null in adults aged 50+ without clinically relevant baseline symptoms; it did not settle deficient or younger populations. | Correct deficiency; do not promise mood prevention. |
| Homeopathic anxiety remedies work. | DOESN’T | Systematic reviews find limited/no anxiety-stress efficacy. | Can delay real care. |
| Kava is a safe natural anxiety fix. | DOESN’T | Mixed benefit plus rare severe liver injury. | Avoid in liver risk, alcohol use, sedatives, pregnancy/lactation. |
| CBD cures anxiety or depression. | DOESN’T | Small heterogeneous trials; better RCTs needed. | Drug interactions and product variability matter. |
| 5-HTP is a safe antidepressant alternative. | DOESN’T | Few reliable studies; long-term safety is uncertain and the cited 2005 review described serotonin syndrome as a theoretical risk. | Avoid serotonergic stacking. |
Popular mental health supplement claims to reject
Read the practical summary
- Homeopathic anxiety remedies: limited and contradictory evidence; not a reliable anxiety treatment.
- CBD cure claims: small, heterogeneous, mixed trials and meaningful drug-interaction concerns.
- Kava as a safe anxiety fix: possible anxiety benefit in some contexts but rare severe liver injury risk.
- 5-HTP mood stacks: weak evidence and a theoretical serotonin-syndrome concern; seek professional advice before combining with serotonergic medicines.
- Evaluation rule: require exact ingredient, exact form, exact dose, exact human evidence, and exact interaction check.
Risks and all side effects
| Ingredient | Common side effects | Rare but serious risks | Who should avoid or use only with clinician input | Source |
|---|---|---|---|---|
| Omega-3 EPA/DHA | Fishy aftertaste, bad breath, heartburn, nausea, loose stools. | Bleeding concerns with anticoagulants/antiplatelets; high-dose atrial fibrillation concern in some literature. | Bleeding disorders, anticoagulant/antiplatelet users, atrial fibrillation history, fish/shellfish allergy, surgery planning. | NIH ODS omega-3 |
| St John’s wort | Diarrhea, dizziness, trouble sleeping, restlessness, skin tingling, photosensitivity. | Serious serotonin-related interactions and loss of effectiveness of critical medicines. Mania-like episodes appear in interaction case reports, but incidence and attribution are uncertain (Mannel review). | Anyone taking antidepressants, oral contraceptives, anticoagulants, immunosuppressants, HIV medicines, cancer medicines, seizure medicines, digoxin, or many chronic medicines; pregnancy/lactation; bipolar disorder. | NCCIH |
| Ashwagandha | Digestive upset, diarrhea, nausea, vomiting, drowsiness. | Liver injury; acute-on-chronic liver failure in vulnerable people has been reported in a case series. | Pregnancy, lactation, liver disease, autoimmune disease, thyroid disease, sedative users, immunosuppressant users. | NCCIH / PMC case series |
| L-theanine | Short trials did not establish a consistent excess of adverse events; common side-effect frequencies and long-term safety remain uncertain. | Long-term risk profile not well established. | Pregnancy/lactation and concurrent medicines require professional advice because safety and interaction data are limited; a clinical sedative interaction was not established by this review. | PubMed review |
| Saffron | Small short-term trials did not show a significant overall adverse-event difference versus placebo or antidepressants. | Long-term, high-dose and rare-event safety remain uncertain. | Pregnancy, complex illness or psychiatric medicines require clinical advice; this review does not establish specific serotonergic or bleeding interactions. | saffron safety review Source |
| Magnesium | Diarrhea, nausea, abdominal cramping. | High-dose toxicity, low blood pressure, heart rhythm problems, respiratory depression in severe toxicity, especially kidney impairment. | Kidney disease, older adults with polypharmacy, antibiotic/bisphosphonate users. | NIH ODS magnesium |
| Vitamin D | Nausea, constipation, weakness, thirst, frequent urination when excessive. | Hypercalcemia, kidney stones, kidney injury, dangerous calcium-related heart rhythm problems. | People with high calcium, kidney disease, thiazide use or high combined calcium/vitamin D intake should review supplementation with a clinician. | NIH ODS vitamin D |
| Kava | Digestive upset, headache, dizziness, drowsiness. | Severe liver injury, liver failure, death or transplant in rare reports. | Liver disease, alcohol use, sedatives, pregnancy/lactation, hepatotoxic medicines, surgery planning. | NCCIH kava / NIH ODS kava |
| CBD | Drowsiness, diarrhea, appetite/weight changes, fatigue. | Liver enzyme elevations and drug interactions; impairment when combined with sedatives or alcohol. | Liver disease, pregnancy/lactation, sedative users, anti-seizure medicine users, anticoagulant users, multiple-medicine users. | CBD adverse effects review / CBD interaction review |
| 5-HTP | Nausea, vomiting and diarrhea; less commonly headache, insomnia or palpitations. | The 2005 review discussed a theoretical serotonin-syndrome risk and uncertain contaminant-associated EMS reports; it did not document human serotonin syndrome from 5-HTP in the reviewed studies. | Seek clinician/pharmacist advice before combining with serotonergic medicines; long-term and special-population safety remains limited. | Cochrane/PMC / safety review Source |
All interactions
| Medication / condition / substance | Interacting supplement(s) | Severity | Mechanism / concern | Action |
|---|---|---|---|---|
| SSRIs, SNRIs, MAOIs, tricyclics, mirtazapine, trazodone, triptans, tramadol, linezolid, lithium, MDMA or serotonergic substances | St John’s wort; precautionary review for 5-HTP or serotonergic blends | Avoid | Serious serotonin-related interactions are documented for St John’s wort. The 2005 5-HTP review described a theoretical risk; the cited saffron reviews do not establish serotonin syndrome. | Do not combine without clinician/pharmacist clearance. |
| Oral contraceptives, transplant immunosuppressants, HIV medicines, cancer medicines, seizure medicines, digoxin, many antidepressants | St John’s wort | Avoid | CYP and P-glycoprotein induction can lower drug exposure and effectiveness. | Avoid unless a prescriber actively manages the interaction. |
| Warfarin, DOACs, aspirin, clopidogrel, NSAID-heavy use, bleeding disorders | Omega-3, St John’s wort and CBD; saffron interactions remain insufficiently studied | Caution/monitor | St John’s wort can reduce anticoagulant exposure or effect; CBD has interaction reports. Omega-3 warrants dose-specific medication review, although clinically significant bleeding was not established overall by the NIH review. The cited saffron review does not establish a bleeding interaction. | Clinician/pharmacist review before use. |
| Benzodiazepines, Z-drugs, opioids, sedating antihistamines, antipsychotics, alcohol | Kava, CBD, ashwagandha and sedating blends; L-theanine interactions remain insufficiently studied | Avoid stacking | Kava, CBD and ashwagandha can cause drowsiness or interact with sedatives. The L-theanine review does not demonstrate additive sedation or respiratory/CNS depression from such combinations. | Avoid alcohol and sedative combinations unless medically supervised. |
| Tetracycline antibiotics, quinolone antibiotics, bisphosphonates | Magnesium | Separate doses | Mineral binding reduces medication absorption. | Separate by prescriber/pharmacist instructions. |
| Thiazide diuretics, digoxin, high-dose calcium | Vitamin D | Monitor | Hypercalcemia risk; calcium shifts may worsen digoxin toxicity risk. | Use labs and clinician guidance. |
| Liver disease, elevated liver enzymes, hepatotoxic medicines | Kava, ashwagandha, CBD, multi-herb blends | Avoid or specialist review | Rare liver injury or liver-enzyme effects. | Avoid self-use; stop and seek care for jaundice, dark urine, itching, pale stools, or upper abdominal pain. |
| Kidney disease | Magnesium, high-dose vitamin D, mineral blends | Medical supervision | Reduced clearance and electrolyte toxicity. | Do not self-dose. |
| Autoimmune disease or immunosuppressants | Ashwagandha, immune “adaptogen” blends | Caution/avoid | Potential immune modulation. | Ask treating clinician. |
| Thyroid disease or thyroid medication | Ashwagandha | Monitor/avoid DIY | Possible thyroid hormone effects. | Use only with thyroid monitoring. |
| Bipolar disorder, mania/hypomania history, psychosis | St John’s wort, 5-HTP, saffron, stimulant/adaptogen blends | Avoid DIY | Mood activation, destabilization, or delayed psychiatric treatment. | Psychiatric review first. |
| Pregnancy, lactation, trying to conceive | St John’s wort, ashwagandha, kava, 5-HTP, CBD, high-dose saffron | Avoid unless clinician-directed | Safety uncertainty or specific harm signals. | Use pregnancy-qualified medical advice only. |
Interaction red flags by supplement
Read the practical summary
- Serotonergic medicines: St John’s wort has documented interactions. Seek precautionary review for 5-HTP; the cited saffron reviews do not establish serotonin syndrome.
- Critical medicines: St John’s wort can lower drug effectiveness through CYP/P-glycoprotein induction.
- Blood thinners: review omega-3 dose and medication monitoring, St John’s wort drug-effect reduction and reported CBD interactions. The cited saffron review does not establish a bleeding interaction.
- Sedatives or alcohol: avoid stacking kava, CBD, ashwagandha or sleep blends. L-theanine combination effects are unestablished; seek medication advice.
- Liver/kidney disease, pregnancy, bipolar symptoms: professional review before any mood supplement.
Funding and influence check
Research funding at a glance
6 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Evidence area | Money / influence risk | How this article handled it |
|---|---|---|
| St John’s wort | Some trials are older, extract-specific, and regionally clustered; herbal manufacturers benefit if results are generalized to all products. | Reported efficacy narrowly and paired every positive statement with serious interaction warnings. |
| Saffron | Hausenblas 2013: Reserveage Organics funding, with two author adviser/consultant ties to a saffron-product business; five small Iran single-center trials. Tóth 2019 declared no conflicts; its official repository record names Hungarian public research grants and an Academy scholarship. Full methods and complete underlying-trial finances remain unverified. | Treat manufacturer-linked positive results as context; no proof of drug equivalence. Source 1 Source 2 |
| Ashwagandha | Many trials use branded extracts or supplement-company involvement; social media demand can amplify weak claims. | Used NCCIH and liver-injury literature to balance benefits with safety limits. |
| CBD | Large commercial market, product heterogeneity, and influencer claims create strong incentive to overstate benefits. | Downgraded to overclaimed until larger independent RCTs support specific uses. |
| Homeopathy | Field-allegiance risk exists, but even CAM-focused reviews do not provide reliable anxiety efficacy. | Classified as no useful evidence for anxiety treatment. |
| Multi-ingredient “happy pill” blends | Proprietary formulas can hide dose logic and rely on ingredient halo effects. | Required exact formula trials; otherwise downgraded. |
Frequently asked questions
What supplement works best for depression?
Selected St John’s wort extracts showed benefit for mild-to-moderate depression in trials, but serious documented interactions make medication review essential (Cochrane St John’s wort, NCCIH St John’s wort). Saffron is promising but less definitive, and no supplement should replace professional care for severe depression.
What supplement works best for anxiety?
No supplement is a first-line replacement for evidence-based anxiety treatment. L-theanine has a plausible short-term stress/anxiety signal, magnesium evidence is suggestive but weak, and kava has safety problems that make casual use hard to justify (L-theanine review, magnesium anxiety review, NCCIH kava).
Is St John’s wort safer than antidepressants?
A general claim that St John’s wort is safer is not justified. Some trials found fewer adverse-effect withdrawals, but serious medication interactions remain; comparative safety depends on the exact extract, medicines and patient (Cochrane St John’s wort, NCCIH St John’s wort).
Are homeopathic anxiety remedies evidence-based?
No reliable evidence supports homeopathic remedies as effective anxiety treatment. A systematic review found evidence limited, contradictory, underpowered, or insufficient for firm conclusions, and a psychiatry review found homeopathy did not show efficacy for anxiety or stress (homeopathy anxiety review, homeopathy psychiatry review).
Is CBD proven for anxiety or depression?
CBD is not proven as a broad anxiety or depression treatment. Recent reviews show possible anxiety signals but emphasize small, heterogeneous, and sometimes contradictory trials, and CBD has drug-interaction concerns (CBD RCT review, CBD interaction review).
Is kava worth trying for anxiety?
Kava is difficult to recommend for self-directed anxiety use because any possible benefit is offset by rare but serious liver injury reports. NCCIH says kava may help anxiety in some contexts but does not appear helpful for generalized anxiety disorder symptoms and has been linked to severe or fatal liver injury (NCCIH kava).
Can I combine several mood supplements?
Some combinations have documented interactions; many others have not been adequately tested. St John’s wort has serious medication/serotonin interactions. CBD, kava and ashwagandha require sedation, liver and medicine checks. The 5-HTP review describes serotonin-syndrome concern as theoretical; the saffron review does not establish specific serotonergic or bleeding interactions. Seek clinician/pharmacist review of the exact products and medicines.
Does vitamin D help if I am deficient?
Correcting vitamin D deficiency is important for health, but vitamin D should not be marketed as a universal depression-prevention supplement. VITAL-DEP found vitamin D3 did not significantly prevent depression or improve mood scores over median 5.3 years in adults aged 50+ without clinically relevant depressive symptoms at baseline (VITAL-DEP, NIH ODS vitamin D).
Supplement decision filter
Read the practical summary
- Are symptoms severe or unsafe? If yes, professional care comes before supplements.
- Is the exact form and dose identified? Avoid vague blends and proprietary “mood matrices.”
- Are there human randomized trials or high-quality reviews? Do not rely on anecdotes, animal data, or influencer claims.
- Were funding and conflicts checked? Product-sponsored evidence is downgraded.
- Were interactions checked? Review medicines, pregnancy, liver/kidney disease, bipolar risk, sedatives, and blood thinners.
Sources
- WHO — Depressive disorder (depression)
- WHO — Anxiety disorders
- Cochrane — St John’s wort for treating depression
- NCCIH — St John’s Wort: Usefulness and Safety
- Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Safety.2004. Source.
- Cochrane — Omega-3 fatty acids for depression in adults
- NCCIH — Omega-3 Supplements: What You Need To Know
- NIH ODS — Omega-3 fatty acids fact sheet
- NCCIH — Ashwagandha: Usefulness and Safety
- Philips et al. Ashwagandha-induced liver injury case series. PMC
- Williams et al. L-theanine stress and anxiety systematic review. PubMed
- Tóth B, Hegyi P, Lantos T, Szakács Z, Kerémi B, Varga G, Tenk J, Pétervári E, Balaskó M, Rumbus Z, Rakonczay Z, Bálint ER, Kiss T, Csupor D. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. 2019. Research record
- Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials.2013. Company funding and adviser/consultant ties disclosed. Source.
- Safety and efficacy of saffron for mild-to-moderate depression. PubMed
- Boyle et al. Magnesium supplementation for subjective anxiety and stress. PubMed
- NIH ODS — Magnesium fact sheet
- Okereke et al. Vitamin D3 and depression risk, VITAL-DEP. PubMed
- NIH ODS — Vitamin D fact sheet
- NCCIH — Kava: Usefulness and Safety
- NIH ODS — Kava safety information
- Pilkington et al. Homeopathy for anxiety and anxiety disorders. PubMed
- Homeopathic treatments in psychiatry systematic review. PubMed
- The impact of cannabidiol treatment on anxiety disorders: RCT review. PubMed
- Therapeutic potential of CBD in anxiety disorders: systematic review/meta-analysis. PubMed
- CBD adverse effects and toxicity. PMC
- CBD interactions with medications and substances. PMC
- Cochrane/PMC — Tryptophan and 5-HTP for depression
- Turner et al. 5-HTP safety review. PubMed
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.